Pamela Esposito, an insider at Kymera Therapeutics Inc (KYMR), sold 1,000 shares of the company's stock on December 16, 2025, at a price of $83.45 per share, resulting in a total transaction value of $83,000. Following this sale, Esposito retains 1,000 shares of Kymera.
Kymera Therapeutics, based in Watertown, Massachusetts, is a biopharmaceutical firm focused on developing small molecule therapeutics that target disease-causing proteins. The company employs 218 full-time staff and went public on August 21, 2020. Its innovative targeted protein degradation (TPD) platform aims to harness the body’s natural cellular recycling system, with a primary focus on immunology. Current programs include KT-621, in a Phase I clinical trial targeting STAT6, and KT-579, an oral degrader of IRF5.
While insider sales can occur for various reasons such as diversification or personal financial needs, they do not inherently signal negative sentiment towards the company. Investors are encouraged to consider insider transactions as part of a broader analysis, examining patterns across multiple insiders and time periods rather than isolated events. Such transactions must be reported to the SEC, providing transparency into the actions of executives and board members.
Kymera Therapeutics has a market capitalization of $4.7 billion and reported an EPS of -3.59. Upcoming earnings reports are anticipated on May 7, 2026, and August 10, 2026, with estimates of -$0.97 and -$1.02 respectively, alongside projected revenues of $10.2 million for both periods.